Dermatol. praxi. 2011;5(1):28-31

Schnitzler syndrome - chronic urticaria + monoclonal gammopathy IgM + osteolytic-osteosklerotic bone changes

prof.MUDr.Zdeněk Adam, CSc.1, MUDr.Luděk Pour, Ph.D.1, MUDr.Marta Krejčí, Ph.D.1, MUDr.Jiří Neubauer2, MUDr.Jiří Prášek, CSc.3, prof.MUDr.Roman Hájek, CSc.1
1 Interní hematoonkologická klinika LF MU a FN Brno
2 Radiologická klinika LF MU a FN Brno
3 Klinika nukleární medicíny LF MU a FN Brno

Schnitzler syndrome is a rare disorder characterized by chronic urticaria, the presence of monoclonal class IgM immunoglobulin, lymphadenopathy

and fevers. We report on a patient who was diagnosed in 1996 and over the next 12 years underwent a number of therapies.

Bone pain associated with proven osteolytic and osteosclerotic lesions resolved on regular bisphosphonate treatment with pamidronate

and, later, clodronate. The patient had transient benefit from treatments with interferon-alpha and with PUVA. No therapeutic effects

were seen with high-dose dexamethasone, 2-chlordeoxyadenosin, cyclosporine, or the combination of bortezomib, thalidomide, and

dexamethasone. However, on therapy with anakinra the patient’s skin symptoms resolved completely and the values of CRP and hemoglobin

normalized.

Keywords: Schnitzler syndrome, gammapathy, urticaria, anakinra

Published: March 17, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adam Z, Pour L, Krejčí M, Neubauer J, Prášek J, Hájek R. Schnitzler syndrome - chronic urticaria + monoclonal gammopathy IgM + osteolytic-osteosklerotic bone changes. Dermatol. praxi. 2011;5(1):28-31.
Download citation

References

  1. Schnitzler L, Hurez D, Verret JL. Urticaire chronique osteoconcensation-macroglobulinemie. Cas Princeps Etude sur 20 ans Ann. Dermatol Venereol 1989; 116: 547-550. Go to PubMed...
  2. Schnitzler L, Schubert B, Boasson M, et al. Urticaire chronique lesions osseuses macroglobulinémie IgM: Maladie de Waldenström? Bull Soc Fr Dermatol Syph. 1974; 81: 363-366.
  3. de Kleijn EM, Telgt D, Laan R. Schnitzler's syndrome presenting as fever of unknown origin (FUO). The role of cytokines in its systemic features. Neth J Med. 1997; 51(4): 140-142. Go to original source... Go to PubMed...
  4. de Koning HD, Bodar EJ, van der Meer JW, Simon A on befalf of the Schnitzler´s Syndrome Study Group. Schnitzler´s syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007; 37(3): 137-148. Go to original source... Go to PubMed...
  5. de Koning HD, Bodar EJ, Simon A, van der Hilst JCH, Netea MG, van der Meer MWM. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis. 2006; 65(4): 542-524. Go to original source... Go to PubMed...
  6. Eiling E, Möller M, Kreiselmaier I, Brach J, Schwarz T. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol. 2007; 57(2): 361-364. Go to original source... Go to PubMed...
  7. Gilson M, Abad S, Larroche C, Dhote R. Treatment of Schnitzler's syndrome with anakinra. Clin Exp Rheumatol. 2007; 25(6): 931. Go to PubMed...
  8. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler´s syndrome with anakinra: Arthritis Rheum. 2005; 52(7): 2226-2227.
  9. Schneider SW, Gaubitz M, Luger TA, et al. Prompt response of refractory Schnitzler´s syndrome to treatment with anakinra. J Am Acad Dermatol. 2007; 56(5 Suppl): S120-S122. Go to original source... Go to PubMed...
  10. Treudler R, Kauer F, Simon JC. Striking effect of the IL-1 receptor antagonist anakinra in chronic urticarial rash with polyclonal increase in IgA and IgG. Acta Derm Venereol. 2007; 87(3): 280-281. Go to original source... Go to PubMed...
  11. Adam Z, Krejčí M, Pour L, et al. Schnitzlerův syndrom, popis čtrnáctiletéh průběhu nemoci a přehled informací o této nemoci Vnitřní Lék. 2008; 12: 1140-1155.




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.